Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The Black-Box Warning (BBW) is the most serious warning that US-FDA can ask for on a drug's labelling. BBWs represent key safety concerns uncovered either during dossier review or post-approval. We have conducted the present study with the primary objective of assessing BBWs issued by the US-FDA.
Methods: BBWs were identified on US-FDA's website from 1st January 2015 to 31st December, 2019. Prescribing information was used to identify and characterize BBWs into new and minor/major updates on a previous BBW. The therapeutic class of the drug, nature [Biological/New Molecular entity (NME)], formulation type, expected duration of use, along with the year of first approval of the molecule with BBWs were evaluated.
Results: A total of n = 167 BBWs were issued by the FDA of which 53 (31.7%) had major updates, 57(34.1%) had minor updates and 57(34.1%) were new BBWs. A total of 137(82%) of BBWs were with NME's whereas 30(18%) were with biologics. Drugs for neurology 40(25.5%)had the highest number of BBWs, followed by oncology 38(24.2%). Among the type of BBWs, cardiovascular risk 31 (15%) were the highest.
Conclusion: Practicing physicians need to understand that benefit-risk of a drug is dynamic and keep abreast of new data related to it.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1574886316666210811161939 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Benefits and Risks of Preprepared Parenteral Nutrition for Early Amino Acid Administration in Premature Infants with Very Low Birth Weight.
Pediatr Gastroenterol Hepatol Nutr
July 2024
Department of Education and Research, Taipei City Hospital, Taipei City, Taiwan.
Purpose: Administering early parenteral amino acids to very low birth weight (VLBW) premature infants (birth body weight [BBW]<1,500 g) is challenging due to factors such as holidays, cost, and access to sterile compounding facilities. Using advance-prepared parenteral nutrition (PN) may address this issue and should be evaluated for its safety and potential benefits.
Methods: We extracted data from medical records collected between July 2015 and August 2019.
Black-Box Warnings of Antiseizure Medications: What is Inside the Box?
Pharmaceut Med
May 2023
CVS Caremark, Woonsocket, RI, 02895, USA.
Antiseizure medications can cause serious adverse reactions and have deleterious drug interactions that often complicate the clinical management of patients. When the US Food and Drug Administration (FDA) wants to alert healthcare providers and patients about the risk of potentially serious or fatal drug reactions, the FDA requires the manufacturers of these medications to format these warnings within a "black-box" border, and prominently display this box on the first section of the package insert; such warnings are called "black-box warnings (BBWs)". The BBW is a way for the FDA to urge physicians to evaluate patients more rigorously and carefully weigh the risks and benefits, before prescribing medication that has the potential to cause serious adverse reactions, and to formulate a plan for close monitoring during therapy.
View Article and Find Full Text PDFImpacts of Semiochemical Traps Designed for Boheman 1833 (Coleoptera: Chrysomelidae) on Nontarget Beneficial Entomofauna in Field Bean Crops.
Insects
February 2023
Functional and Evolutionary Entomology, University of Liège-Gembloux Agro-Bio Tech, Passage des Déportés, 2, 5030 Gembloux, Belgium.
Broad bean weevils (BBWs-Coleoptera: Chrysomelidae) are serious pests of field bean seeds that hamper the promotion of this crop in the diversification of European cropping systems. Recent research has identified different semiochemical lures and trap devices for the development of semiochemical-based control strategies of BBWs. In this study, two field trials were carried out in order to provide necessary information supporting the implementation of sustainable field use of semiochemical traps against BBWs.
View Article and Find Full Text PDFRisk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies.
Mayo Clin Proc Innov Qual Outcomes
February 2022
Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic, Scottsdale, AZ.
Objective: To estimate the potential risk for a future postmarket black box warning (BBW) of US Food and Drug Administration (FDA)-approved monoclonal antibodies (mAbs) because of the importance for medical clinicians to understand mAb risks and benefits, including unknown future risks, especially for recently approved mAbs.
Methods: The complete dates of the study were March 16, 2020, through May 12, 2021. We searched the FDALabel database online and reviewed the scientific literature to determine current and previous FDA-approved mAbs as of March 2020.
An Audit of Black Box Warnings (BBWs) in the United States Food and Drug Administration (US-FDA) Database - A Five-Year Analysis.
Curr Drug Saf
May 2022
Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Mumbai, India.
Background: The Black-Box Warning (BBW) is the most serious warning that US-FDA can ask for on a drug's labelling. BBWs represent key safety concerns uncovered either during dossier review or post-approval. We have conducted the present study with the primary objective of assessing BBWs issued by the US-FDA.
View Article and Find Full Text PDF